Elucent Medical Announces New Partnership with Survingnreastcancer.0rg

Elucent Medical, a pioneering medical device company specializing in developing innovative solutions for sensitive cancer screening techniques that transform patient care, today announced that it has partnered with SurvivingBreastCancer.org (SBC) and become a sponsor of the educational and virtual community. The two organizations were brought together by breast surgical oncologist Jandie Posner, D.O. because of their shared commitment to and passion for educating breast cancer patients about their resources, care and community support.

“I have been using the EnVisio Surgical Navigation System for more than two years. The device offers unparalleled precision in the operating room,” said Dr. Posner, Chief of Breast Surgery and Interim Medical Director of the Crozer Health Breast Program in Upland, Pennsylvania. “I also work closely with SurvivingBreastCancer.org as a Medical Advisor and strongly advocate for their mission of supporting patients through survivorship and thriver-ship. I saw the prospect of bringing Elucent and SBC together as a serendipitous opportunity based on a natural connection.”

Dr. Posner introduced Elucent Medical’s leadership teams to Laura Carfang, founder of SurvivingBreastCancer.org and a breast cancer survivor herself, to facilitate the partnership, supporting SBC’s goal of filling the gaps in breast cancer support, education and resources.

“We cannot do our work without our colleagues across industry verticals, the breast cancer community, medical providers, and industry leaders such as Elucent,” said Carfang. “We look forward to working with Elucent to expand our reach and impact on the lives of those we serve, beginning with the device company providing the books for our monthly Breast Cancer Book Club and resources about surgical care for our patients.”

The Breast Cancer Book Club is a non-traditional support group where patients can feel accepted, supported and appreciated as people and not just patients or survivors. Dr. Posner founded the book club at SBC more than four years ago.

“Though we are starting this relationship during breast cancer awareness month, we are fully aware that the needs of patients is ongoing the other 11 months of the year,” said Jason Pesterfield, CEO of Elucent. “We are grateful to Dr. Posner for bridging our two organizations and proud to be embarking on this new relationship with SBC. We look forward to growing our partnership, seeing how else we can support the vast community of those impacted by breast cancer.”

About the EnVisio® Navigation System

EnVisio is the first of its kind surgical navigation system, providing three-dimensional stereotactic guidance, returning the physician back to the site of cancerous tissue for removal. The novel device utilizes an innovative, differentiated electromagnetic field, coupled with wireless SmartClip® technology. The SmartClip emits a unique signature that enables surgeons to target a specimen (plus margin) at the time of surgical intervention. Unprecedented precision within a wide field of view leads the surgeon directly to the target of interest. Broaden the treatable patient population by expanding SmartClip localization to all soft tissue, with a focus on expanding the platform into lung surgery in the future.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy